Sanofi has finalized its $1.7 billion acquisition of Inhibrx, a clinical-stage biotech company, expanding its pipeline in oncology and rare diseases. Inhibrx shareholders will receive $30 per share, with an additional $5 per share contingent on a regulatory milestone. The acquisition includes the addition of SAR447537, a protein therapy aimed at treating alpha-1 antitrypsin deficiency (AATD). Inhibrx’s stock will be delisted from NASDAQ. The acquisition reflects growing trends in biopharma M&A, despite regulatory scrutiny from bodies like the FTC. Analysts see this activity as a strategic move to counteract challenges posed by the Inflation Reduction Act (IRA).

Biotechnology, Pharmaceuticals, Healthcare M&A,United States, France